JP Morgan Upgrades C4 Therapeutics to Neutral, Announces $6 Price Target
Benzinga · 01/29 10:45
JP Morgan analyst Eric Joseph upgrades C4 Therapeutics (NASDAQ:CCCC) from Underweight to Neutral and announces $6 price target.